文献速递重症综合管理与镇静镇痛心脑血管急症

衰弱对院外心脏骤停后死亡率、功能结局和健康状况的影响:TTM2试验的见解

Impact of frailty on mortality, functional outcome, and health status after out-of-hospital cardiac arrest: insights from the TTM2-trial.
PubMed 文献 · Intensive Care Med · 2025-11-10
一句话结论在TTM2试验中,衰弱与院外心脏骤停后6个月和24个月死亡及不良功能结局风险显著增加相关,衰弱程度越重风险越高。

本文为TTM2试验(国际、前瞻性、多中心研究)的基于队列的二次分析,纳入1861例院外心脏骤停患者,用临床衰弱量表(1-9分)将患者分为健壮(1-3分)、衰弱前期(4分)、衰弱(5分)和严重衰弱(6-9分)。主要结局为6个月和24个月死亡率和不良功能结局(改良Rankin量表4-6分)。结果显示,与健壮者相比,衰弱前期、衰弱和严重衰弱者的6个月死亡率调整OR分别为2.7、3.7和8.9,不良功能结局调整OR分别为2.9、3.9和35.4。严重衰弱者接受神经预后评估较少,而衰弱前期、衰弱和严重衰弱者放弃维持生命治疗更常见。结论提示衰弱与院外心脏骤停后死亡和不良功能结局风险显著增加相关。

要点

  • 在1861例院外心脏骤停患者中,13%为衰弱前期,10%为衰弱或严重衰弱。
  • 与健壮者相比,衰弱前期、衰弱和严重衰弱者6个月死亡率调整OR分别为2.7(95%CI 1.8-3.8)、3.7(95%CI 1.9-7.1)和8.9(95%CI 4.2-18.7)。
  • 与健壮者相比,衰弱前期、衰弱和严重衰弱者6个月不良功能结局(改良Rankin量表4-6分)调整OR分别为2.9(95%CI 1.9-4.2)、3.9(95%CI 1.9-8.1)和35.4(95%CI 8.4-148.8)。
  • 严重衰弱者接受神经预后评估较少(p < 0.001),衰弱前期、衰弱和严重衰弱者放弃维持生命治疗更常见(p < 0.001)。
  • 衰弱前期和衰弱幸存者似乎更常报告功能下降和较低健康状况,但存在个体差异。

适用人群与场景

  • 院外心脏骤停后入住ICU的患者,来自TTM2试验(国际、前瞻性、多中心研究)。
  • 纳入1861例参与者,用临床衰弱量表(1-9分)评估衰弱:健壮(1-3分)、衰弱前期(4分)、衰弱(5分)、严重衰弱(6-9分)。

诊断标准与关键阈值

  • 衰弱评估采用临床衰弱量表(Clinical Frailty Scale,1-9分):健壮1-3分,衰弱前期4分,衰弱5分,严重衰弱6-9分。
  • 不良功能结局定义为改良Rankin量表(modified Rankin Scale)4-6分。

研究设计与关键结果

  • 研究类型:TTM2试验的基于队列的二次分析,国际、前瞻性、多中心研究。
  • 样本量:1861例参与者;衰弱前期240例(13%),衰弱或严重衰弱188例(10%)。
  • 主要终点:与健壮者相比,6个月死亡率调整OR:衰弱前期2.7(95%CI 1.8-3.8),衰弱3.7(95%CI 1.9-7.1),严重衰弱8.9(95%CI 4.2-18.7);6个月不良功能结局调整OR:衰弱前期2.9(95%CI 1.9-4.2),衰弱3.9(95%CI 1.9-8.1),严重衰弱35.4(95%CI 8.4-148.8)。
  • 关键次要终点:严重衰弱者接受神经预后评估较少(p < 0.001);放弃维持生命治疗在衰弱前期、衰弱和严重衰弱者中更常见(p < 0.001);衰弱前期和衰弱幸存者似乎更常报告功能下降和较低健康状况,但存在个体差异。
  • 24个月死亡率和不良功能结局结果未在摘要中报告。

证据类型、等级与局限

  • 证据类型:国际、前瞻性、多中心试验的基于队列的二次分析。
  • 试验注册号:NCT02908308。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,衰弱与院外心脏骤停后死亡和不良功能结局风险显著增加相关,衰弱幸存者似乎更常出现功能下降和较低总体健康状况。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: To explore the association of frailty with mortality, functional outcome, and health status after out-of-hospital cardiac arrest.

METHODS: This is a cohort-based secondary analysis of the Targeted Hypothermia versus Targeted Normothermia after out-of-hospital cardiac arrest (TTM2) trial, an international, prospective, multicentre study. Frailty was assessed using the Clinical Frailty Scale (1-9): fit (1-3), prefrail (4), frail (5), and severely frail (6-9). Main outcomes were mortality and poor functional outcome (modified Rankin Scale 4-6) at 6 and 24 months. Additional outcomes included neuroprognostication, withdrawal-of-life-sustaining-therapies (WLST), functional decline (retrospectively reported pre-arrest versus 6 month Glasgow Outcome Scale Extended score), health status (EQ-5D-5L, EQ-VAS), and life satisfaction at 6 and 24 months.

RESULTS: Of 1861 participants, 240 (13%) were prefrail, and 188 (10%) were frail or severely frail. Mortality and poor functional outcome increased significantly with greater frailty. Compared to fit participants, adjusted ORs (95% CI) for 6 month mortality were: prefrail 2.7 (1.8-3.8), frail 3.7 (1.9-7.1), and severely frail 8.9 (4.2-18.7); and poor functional outcome: prefrail 2.9 (1.9-4.2), frail 3.9 (1.9-8.1), and severely frail 35.4 (8.4-148.8). Severely frail participants underwent neuroprognostication less often (p < 0.001), while WLST was more common in the prefrail, frail and severely frail (p < 0.001). Prefrail and frail survivors tended to report more frequent functional decline and lower health status, though with individual variation.

CONCLUSION: Frailty was associated with a significantly increased risk of mortality and poor functional outcome after out-of-hospital cardiac arrest. Findings suggest more frequent functional decline and lower overall health status in frail survivors.

TRIAL REGISTRATION: NCT02908308.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Göbel Andertun S, Wissendorff-Ekdahl A, Ullén S, et al. Impact of frailty on mortality, functional outcome, and health status after out-of-hospital cardiac arrest: insights from the TTM2-trial. Intensive Care Med. 2025. PMID: 41212202. doi:10.1007/s00134-025-08185-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。